Abstract-Torasemide is a loop diuretic that is effective at low once-daily doses in the treatment of arterial hypertension.
R ecent long-term clinical studies have demonstrated the beneficial effects of low-dose diuretics in reducing cardiovascular morbidity and mortality in the treatment of hypertension. 1, 2 Therefore, diuretics continue to be recommended as first-line agents in the treatment of hypertension. 3 It has been suggested that the long-term antihypertensive effectiveness of diuretics is due to its ability to reduce peripheral resistance through a direct arteriolar vasodilator action. 4 Animal experiments have shown that diuretics reduce the vascular responsiveness to vasoconstrictor agonists like norepinephrine and angiotensin II (Ang II). 5, 6 In addition, in hypertensive patients it was shown that long-term use of diuretics desensitizes the vasculature in its response to endogenous vasoconstrictor hormones. 7 Torasemide is a pyridil sulfonil urea class compound whose chemical structure places it between loop diuretics and Cl Ϫ channel blockers. 8 The main tubular site of action of torasemide is the ascending limb of the loop of Henle, where it interacts with the Na ϩ , 2Cl Ϫ , K ϩ cotransporter localized in the luminal surface. 8, 9 By this interaction, at high doses, torasemide inhibits NaCl reabsorption which provokes diuresis. 10 Torasemide is used as a first-line therapy in hypertension, and the results of several prospective therapeutic trials demonstrate that this compound reduces blood pressure at dosages that do not result in documented natriuresis. [11] [12] [13] Therefore, the antihypertensive mechanism of action of torasemide may be based not only on the elimination of salt and water from the body, but also on an arterial vasodilator action. This possibility is in agreement with previous in vivo and in vitro experiments showing that loop diuretics, such as furosemide, 14, 15 and Cl Ϫ channel blockers, such as diphenylamine-2-carboxylate, 16, 17 exert vasorelaxation effects.
Therefore, we hypothesized that torasemide exerts a vasorelaxation effect by interfering with the vascular actions of Ang II. To test this hypothesis we examined the in vitro effects of torasemide on both Ang II-induced isometric contraction in aortic rings from spontaneously hypertensive rats (SHR) and Ang II-induced intracellular free calcium concentration ([Ca 2ϩ ] i ) transients in cultured vascular smooth muscle cells (VSMC) from the aorta of SHR.
Methods

Animals
The study was performed with 30-week-old male SHR obtained from RCC Biotechnology & Animal Breeding (Fullinsdorf, Switzerland). The rats were housed in cages maintained in a humidity-and temperature-controlled room and fed a standard diet. They had access to tap water ad libitum. The investigation was performed according to the European Community guidelines for animal ethical care and use of laboratory animals (Directive 86/609). Before the rats were euthanized by decapitation, the systolic blood pressure was measured by the standard tail-cuff method. Recorded systolic blood pressure values were in agreement with those previously described in this animal model at this age (214Ϯ5 mm Hg, meanϮSEM of 15 rats).
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Preparation of Isolated Endothelium-Denuded Aortic Rings
The thoracic aorta was removed immediately after euthanization, cleaned, and placed into Krebs-Heinseleit solution of the following composition (mol/L): 118. 
Study of Vasoactive Responses
Cumulative concentration-response curves for the response to 10
Ϫ9
to 10 Ϫ6 mol/L Ang II were obtained in order to determine a concentration of submaximal contraction and the pD 2 value. In a second group of experiments, the aortic rings were incubated for 30 minutes with different concentrations of torasemide, furosemide, and irbesartan (10 Ϫ10 , 10 Ϫ8 , 10 Ϫ6 mol/L). After the incubation, a contraction induced by a submaximal concentration of Ang II was tested. Each preparation was exposed to only 1 concentration of the drugs used and only to a single concentration of the agonist, to avoid possible receptor desensitization. One aortic ring per rat was reserved to obtain control responses (100%) in the presence of the solvent.
Cell Isolation and Culture
Primary VSMCs were obtained from the thoracic aorta of adult SHR and cultured by the tissue explants method in accordance with previously published procedures. 19 Briefly, the smooth muscle tissue was longitudinally opened and cut in small pieces that were grown in plastic 6-well plates and maintained at 37°C in a humidified incubator with an atmosphere of 95% air, 5% CO 2 . Tissue explants were cultured in Dulbecco's modified Eagle's medium containing 20% fetal bovine serum and antibiotic-antimycotic (10 000 U/mL penicillin G sodium, 10 000 g/mL streptomycin sulfate and 25 g/mL amphotericin B as fungizone R in 0.85% saline). When VSMCs began to emerge from the explants, they were subcultured with 0.05% trypsin to a 25 cm 2 flask. After the first subculture, cells were subcultured every week and reached confluence in 5 to 6 days. The medium was changed initially after 24 hours and then every 3 to 4 days. The culture was continued up to 8 passages with 5% fetal bovine serum and antibiotic. Immunocytochemical characterization of isolated VSMCs was performed on primary cultures by use of specific antibodies against smooth muscle specific ␣-actin (Dako Ltd).
Measurement of [Ca 2؉ ] i in VSMCs
Measurement of [Ca 2ϩ ] i was performed with nonconfluent cultures of VSMCs grown on 12 mm round coverslips that were rendered quiescent by deprivation of serum for 48 hours. Afterward, each coverslip was incubated in a humidified incubator for 45 minutes with fura-2-AM, 4 mol/L dissolved in DMSO with 0.02% pluronic acid. Unincorporated fura-2 was removed by giving each coverslip two 15- ] i transients were measured. To test their effects in vitro, all drugs were weighed and dissolved in water or in DMSO on the day of the experiment.
Statistical Analysis
Values are given as meanϮSEM. Statistical differences between mean values were determined with 1-way ANOVA followed by Student-Newman-Keuls test. When the number of data was less than 10, the statistical analysis was performed with Mann-Whitney U test. A P value Ͻ0.05 was considered statistically significant. Concentration-response curves were fitted by nonlinear regression, and a concentration giving 50% of the maximal response (EC 50 ) was determined and pD 2 calculated as ϪLog EC 50 (mol).
Results
Responses to Ang II in Endothelium-Denuded Aortic Rings
Ang II evoked concentration-dependent increases in vascular tone in aortic rings from SHR (Figure 1a) . The calculated pD 2 value was 7.5Ϯ0.3. On the basis of these concentrationresponse curves, a concentration of 10 Ϫ7 mol/L was chosen to carry out the next experiments, because this concentration is critically located on the curve. Different levels of maximal tension were obtained either by stepwise cumulative addition of Ang II or by the addition of a single concentration of Ang
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II. These data suggest that there was tachyphylaxis to Ang II responses during the cumulative concentration-response curve in this tissue.
Effects of Torasemide on Ang II-Induced Responses in Endothelium-Denuded Aortic Rings
The ability of torasemide to induce relaxation of norepinephrine-precontracted rings was tested. The percentage of relaxation (40%) induced by torasemide in rings from SHR was observed only at a high concentration (10 Ϫ4 mol/L); it was considered to be a nonspecific response and probably caused by the solvent, as previously suggested by others. 21 Torasemide inhibited, in a dose-dependent way, the vasoconstriction induced by Ang II (10 Ϫ7 mol/L) in aortic rings from SHR, IC 50 ϭ0.5Ϯ0.04 mol/L (Figure 1b) . The inhibition of Ang II-induced contractile response almost reached 50% at 10 Ϫ6 mol/L torasemide (Table) . As Figure 2 shows, a single concentration of Ang II (10 Ϫ7 mol/L) caused a prompt and brief contraction of the aortic rings from SHR with a maximum value of 116.6Ϯ10 mg (nϭ22). This value was reached 2 or 3 minutes after the beginning of incubation with the agonist (Figure 2a) . A 30 minute period of incubation with torasemide (10 Ϫ6 mol/L) significantly inhibited the Ang II-induced vasoconstriction (Figure 2b ). 
Basal and Ang II-Induced [Ca 2؉ ] i Responses in VSMCs
Effects of Furosemide and Irbesartan on Ang II-Induced Vascular Responses
Furosemide and irbesartan inhibited, in a dose-dependent way, the vasoconstriction induced by Ang II (10 Ϫ7 M) in aortic rings from SHR (Table) . Whereas irbesartan inhibited the Ang II-induced [Ca 2ϩ ] i stimulation in a dose-dependent way, furosemide did not exert any effect on this parameter (Table) . Results are expressed as percentage of inhibition (%) of the response to Ang II (10 Ϫ7 mol/L) in control conditions. Values are meanϮSEM from 4 to 6 preparations. *PϽ0.05 vs irbesartan; †PϽ0.05 vs irbesartan and torasemide.
Inhibitory Effects of Different Concentrations of Torasemide, Furosemide and Irbesartan on Ang II-Induced Vascular and Intracellular Responses in SHR
Discussion
The main finding of the current study is that pharmacological concentrations of torasemide inhibit Ang II-induced fast contraction in endothelium-denuded aortic rings from SHR. Furthermore, we did observe that pharmacological concentrations of torasemide block Ang II-induced rapid increase in [Ca 2ϩ ] i in cultured VSMCs of the aorta from SHR. Central to the direct vasoconstrictor action of Ang II on smooth muscle is its capacity to increase [Ca 2ϩ ] i . Following the interaction with the Ang II type 1 receptor (AT 1 ), Ang II mobilizes Ca 2ϩ by releasing Ca 2ϩ sequestered intracellularly and by increasing Ca 2ϩ influx from the extracellular compartment. The former event may occur by way of phosphoinositide turnover, and the latter may occur in association with voltage-sensitive Ca 2ϩ channels. 23, 24 As a consequence, [Ca 2ϩ ] i increases and contraction in VSMCs ensues. The occurrence of this sequence of events is confirmed by our results with the AT 1 antagonist irbesartan. Because of its physicochemical properties, it is unlikely that torasemide directly antagonizes the binding of Ang II to the AT 1 in VSMCs. 25 Therefore, other mechanisms may be influenced by the drug.
Sodium and other ions influence Ang II binding and, therefore, modulate hormone-receptor signaling. 26 The Na ϩ , 2Cl Ϫ , K ϩ cotransport system is but one of several means by which Na ϩ transport regulates Ang II-receptor interaction. An Na ϩ /H ϩ antiporter, an Na ϩ /Ca ϩ antiporter, and an Na ϩ channel have also been described. 27, 28 Torasemide might inhibit the Na ϩ , 2Cl Ϫ , K ϩ cotransport system in VSMCs as it does in tubular cells. 29, 30 Thus, the blockade of this cotransporter would reduce the cytosolic Na ϩ activity, and this, in turn, would interfere with Ang II-AT 1 signaling in VSMCs. This is further supported by our observation that another inhibitor of the cotransporter, furosemide, also interferes with the vasoconstrictor activity of Ang II. Interestingly, the activity of the Na ϩ , 2Cl Ϫ , K ϩ cotransport system has been reported to be abnormally increased in VSMCs 31 and erythrocytes 32 from SHR. Furthermore, it has been found that torasemide derivatives, which inhibit the activity of the Na ϩ , 2Cl Ϫ , K ϩ cotransport system, prevent the development of hypertension in SHR. 33 Whether the cotransporter abnormality is also present in VSMCs from hypertensive patients, as it is in erythrocytes from them, 34 and whether this can be 
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corrected by torasemide and other loop diuretics in vivo deserve further investigation. Unlike furosemide and other loop diuretics, the chemical structure of torasemide is similar to that of the Cl Ϫ channel blockers. It has recently been described that Ang II stimulates the opening of Cl Ϫ channels in VSMCs resulting in a Cl Ϫ efflux and consequent membrane depolarization. 16 This process would drive the opening of voltage-gated Ca 2ϩ channels, Ca 2ϩ influx, and vasoconstriction. 35 It has been shown that torasemide inhibits Cl Ϫ conductance in epithelial cells. 10 Interestingly, sulfonic derivatives have been shown to block Cl Ϫ channels in VSMCs from the rat aorta. 36 Our observation that torasemide inhibits Ang II-induced [Ca 2ϩ ] i increase in VSMCs more potently than does furosemide suggests that the blockade of Cl Ϫ channels may be an additional mechanism involved in the ability of torasemide to interfere with the vasoactive actions of Ang II.
Results presented here indicate that torasemide alone is not able to induce relaxation of precontracted endotheliumdenuded aortic rings from SHR. Because the endothelium was removed in our preparation, this finding does not exclude the possibility that torasemide exerts a direct vasorelaxation effect on the intact wall. This is supported by previous experiments which show that torasemide increased the content of cGMP in VSMCs of the aorta from renal hypertensive rats. 37 In addition, torasemide has been shown to enhance prostacyclin secretion in primary cultured human endothelial cells. 38 In summary, the results of the present study presented here indicate that torasemide inhibits Ang II-induced contraction of aortic strips from SHR. Our findings also suggest that torasemide interferes with Ang II-dependent mechanisms which lead to the stimulation of [Ca 2ϩ ] i in VSMCs. Further experiments are necessary to make the roles of Cl Ϫ channels and/or the Na ϩ , 2Cl Ϫ , K ϩ cotransporter in these vascular actions of torasemide more precise. The in vitro data presented here may add further information to the in vivo antihypertensive effects of nonnatriuretic dosages of torasemide. 
